Roche posts SKYSCRAPER-01 results for tiragolumab/atezolizumab; registers Phase II Parkinson's trial

Roche had two notable registry updates for the week of November 9, 2026, one with results posted and one newly registered.

• Tiragolumab plus atezolizumab versus placebo plus atezolizumab, Phase III, in previously untreated PD-L1-selected non-small cell lung cancer: the study, known as "SKYSCRAPER-01," is listed as completed, evaluating efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in patients with previously untreated locally advanced, unresectable or metastatic PD-L1-selected non-small cell lung cancer with no EGFR mutation or ALK translocation.¹ The trial enrolled 620 participants, randomized to receive atezolizumab followed by tiragolumab or placebo every three weeks until disease progression, loss of clinical benefit, or unacceptable toxicity.¹ Results were first posted November 9, 2026.
• RO7568282, Phase II, in early-stage Parkinson's disease: the trial, acronym "TARBELA-PD," is designed to evaluate the efficacy, safety, and pharmacokinetics of RO7568282 compared with placebo in participants with early-stage Parkinson's disease on stable symptomatic monotherapy with levodopa.² The study is recruiting, with an estimated enrollment of 474 participants², and an estimated start date of November 10, 2026.